| Title |
Fewer Reoperations After Lumpectomy for Breast Cancer with Neoadjuvant Rather than Adjuvant Chemotherapy: A Report from the National Cancer Database
|
|---|---|
| Published in |
Annals of Surgical Oncology, January 2017
|
| DOI | 10.1245/s10434-016-5760-8 |
| Pubmed ID | |
| Authors |
Jeffrey Landercasper, Barbara Bennie, Benjamin M. Parsons, Leah L. Dietrich, Caprice C. Greenberg, Lee G. Wilke, Jared H. Linebarger |
| Abstract |
Reoperations occur frequently after initial lumpectomy for breast cancer. The authors hypothesized that the receipt of neoadjuvant chemotherapy (NAC) is associated with fewer reoperations. The association between timing of chemotherapy and reoperation rates (ROR) after lumpectomy was investigated for patients with stages 1-3 breast cancer in the National Cancer Database (NCDB) from 2010 to 2013 by multivariable logistic regression modeling. Then propensity score-matching was performed. The unadjusted ROR for 71,627 stages 1-3 patients was 11.4% for those who had NAC compared with 20.3% for those who had postoperative chemotherapy (p < 0.001) (odds ratio [OR] 0.53; 95% confidence interval [CI] 0.49-0.57; p < 0.001). The ORs for the reoperations performed for patients with stages 1, 2, and 3 cancers who received NAC were respectively 0.65 (95% CI 0.56-0.75), 0.50 (95% CI 0.45-0.56), and 0.27 (95% CI 0.19-0.38) The p values for all were lower than 0.001. For a population of patients receiving chemotherapy, the receipt of chemotherapy before instead of after surgery was associated with fewer reoperations after initial lumpectomy for breast cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 13% |
| Researcher | 4 | 13% |
| Other | 3 | 10% |
| Student > Postgraduate | 3 | 10% |
| Professor | 3 | 10% |
| Other | 7 | 23% |
| Unknown | 7 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 42% |
| Nursing and Health Professions | 4 | 13% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Business, Management and Accounting | 1 | 3% |
| Linguistics | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 6 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2017.
All research outputs
#22,226,848
of 24,803,011 outputs
Outputs from Annals of Surgical Oncology
#6,022
of 7,031 outputs
Outputs of similar age
#367,188
of 430,937 outputs
Outputs of similar age from Annals of Surgical Oncology
#67
of 67 outputs
Altmetric has tracked 24,803,011 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,031 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 430,937 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.